Vaxart Secures European Patent For Oral Norovirus Vaccine Through 2036

Vaxart (VXRT) said the European Patent Office (EPO) granted a new patent extending intellectual property protection for its norovirus oral vaccine program through at least the remainder of the patent term (exact date not fully shown). The approval supports longer-run commercial defensibility of the program, which is modestly positive for valuation despite being incremental versus a clinical or regulatory milestone.